Kristin Furle
Heidelberg, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Full-length merozoite surface protein 1 formulated with GLA-SE adjuvant in malaria pre-exposed adults: a randomised, controlled, double-blind, parallel-group, single-centre Phase Ib trial.
Journal: EClinicalMedicine
Published: July 07, 2025
Controlled human malaria infection in adults identify combinations of merozoite antigens associated with clinical immunity.
Journal: Nature communications
Published: March 24, 2025
IgG Subclass Switch in Volunteers Repeatedly Immunized with the Full-Length Plasmodium falciparum Merozoite Surface Protein 1 (MSP1).
Journal: Vaccines
Published: January 23, 2024
Plasmodium falciparum merozoite surface protein 1 as asexual blood stage malaria vaccine candidate.
Journal: Expert review of vaccines
Published: December 15, 2023
Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.
Journal: Science translational medicine
Published: February 08, 2023
Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine.
Journal: NPJ vaccines
Published: January 26, 2023
Full-length MSP1 is a major target of protective immunity after controlled human malaria infection.
Journal: Life science alliance
Published: January 08, 2023
Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria.
Journal: Nature communications
Published: February 08, 2021
Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.
Journal: NPJ vaccines
Published: September 23, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026